

Tacrolimus

S

Acute kidney injury: case report

In a multicenter, retrospective study involving 359 patients receiving remdesivir for COVID-19 between 11 May 2020 and 18 October 2020, a patient [*age and sex not stated*] was described, who developed acute kidney injury following tacrolimus toxicity during treatment with tacrolimus. The patient with impaired renal function and SARS-CoV-2 infection, was undergoing treatment with remdesivir. The patient was also receiving tacrolimus [*indication, dosage and route not stated*]. The patient subsequently developed acute kidney injury secondary, attributed to tacrolimus toxicity or contrast-induced nephropathy [*duration of treatment to reaction onset and outcome not stated*].

Ackley TW, et al. A valid warning or clinical lore: An evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. *Antimicrobial Agents and Chemotherapy* 65: e02290-20, No. 2, 20 Jan 2021. Available from: URL: <http://doi.org/10.1128/AAC.02290-20> 803552766